How long can patients stay on Skyrizi?
Skyrizi (risankizumab-rzaa) has no fixed time limit for use. Patients can continue treatment indefinitely if it remains effective and safe, as determined by their doctor. The drug is approved for chronic conditions like moderate-to-severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis, where ongoing therapy often controls symptoms long-term.[1]
What do clinical trials show for long-term use?
In the psoriasis pivotal trials, patients received Skyrizi for up to 52 weeks, with 89-94% maintaining clear or almost clear skin at week 52.[1] Extension studies extended this to 2.5 years, showing sustained efficacy and a safety profile consistent with shorter-term data—no new risks emerged.[2] Crohn's disease trials included maintenance up to 52 weeks, with 40-60% in remission.[3] Real-world data supports multi-year use without predefined stops.
When do doctors recommend stopping Skyrizi?
Discontinuation typically occurs if the drug loses effectiveness (secondary failure), side effects become intolerable, or the condition enters sustained remission. For psoriasis, some patients taper after 1-2 years of clear skin, but relapse is common upon stopping. No official guidelines mandate a maximum duration—decisions follow individual response monitoring every 3-6 months.[1][4]
What are the risks of long-term Skyrizi use?
Common side effects (upper respiratory infections, headache, fatigue) occur in 10-20% of patients and do not increase over time. Serious risks like infections or hypersensitivity remain rare (<1%) across years of exposure. No evidence of cumulative toxicity in trials up to 3+ years, but long-term cancer or organ damage risks are not fully studied beyond 5 years.[1][2] Regular blood tests monitor for issues.
How does Skyrizi dosing work over time?
Induction: Weeks 0 and 4 for psoriasis (150 mg subcutaneous) or Crohn's (600 mg IV). Maintenance: Every 12 weeks indefinitely. This schedule supports years of use with self-injection pens for convenience.[1]
Skyrizi patent and availability timeline
Skyrizi's core composition patent (US 8,436,140) expires in 2027, with others extending to 2032-2037. Pediatric exclusivity adds 6 months. Biosimilars unlikely before 2033 due to method and formulation patents.[5] No impact on current patients staying on brand-name Skyrizi.
[1] Skyrizi Prescribing Information, AbbVie, 2024. https://www.skyrizi.com/content/dam/celgene-site/products/pi/pi-skyrizi.pdf
[2] Reich et al., Lancet 2020;395:962-72 (long-term psoriasis extension).
[3] Ferrante et al., Lancet 2022;399:2011-24 (Crohn's maintenance).
[4] American Academy of Dermatology guidelines on psoriasis biologics, 2023.
[5] DrugPatentWatch.com. https://www.drugpatentwatch.com/p/tradename/SKYRIZI